|By Marketwired .||
|February 13, 2014 02:17 PM EST||
CARLSBAD, CALIFORNIA -- (Marketwired) -- 02/13/14 -- Aurora Spine Corporation (TSX VENTURE:ASG) announced today the appointment of Mike Keegan to the newly created position of Executive Vice President, U.S. Sales. Mr. Keegan will be responsible for the Company's U.S. sales efforts, including the oversight of strategic sales development, sales administration, adding divisional sales directors and sales training. He will also serve as a member of Aurora Spine's Executive Management Team.
Prior to joining Aurora, Mr. Keegan served as Director of U.S. Sales for Lanx, a designer, manufacturer, and supplier of spinal devices and biologics. Mr. Keegan has over 25 years of sales and marketing experience.
Mr. Keegan served as Area Director for Globus Medical, District Sales Manager for Medtronic and held various sales, marketing, management and international roles with Boston Scientific Corporation. Mr. Keegan began his sales career with the Xerox Corporation. He has a proven track record of building dynamic and highly successful sales teams. He received a B.A. degree from Providence College and an MBA from Boston University.
Trent J. Northcutt, President and Chief Executive Officer, said, "Mike Keegan's experience as a medical sales executive, with a proven track record to create and lead successful and dynamic sales teams, will be a tremendous asset to Aurora Spine. We believe his background and extensive knowledge of the spine industry will allow him to seamlessly integrate into this new role. Mike will focus on further strengthening our sales and distribution network as we continue to make rapid progress on the creation of a hybrid sales force consisting of direct sales employees and independent distributors. I am confident that Mike will lead our sales team to maximum performance in 2014 and beyond."
About Aurora Spine
Aurora Spine is an early stage company focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed success of the company's sales efforts. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.
Aurora Spine Corporation
President and Chief Executive Officer
Aurora Spine Corporation
Chief Financial Officer